The management of disseminated testicular cancer.
Fourteen patients with disseminated non-seminomatous germ cell tumours of the testis were treated with a 3-drug combination of vinblastine, bleomycin and cis-diamminedichloroplatinum. Of 13 patients with measurable disease, 9 (69%) had complete and 3 (23%) partial remission. One patient with a solitary metastasis failed to respond but is disease-free following surgical excision. Toxicity was significant but no drug-related deaths occurred and there were no apparent lasting side effects. No patient attaining complete remission has relapsed. Eleven (79%) of the 14 patients are without evidence of disease from 3+ to 36+ months, 6 of these for 2 years or more. Of the patients in partial remission one died at 16 months and one is undergoing further treatment for relapse with liver metastases. One patient remains in partial remission at 30 months. These results demonstrate the efficacy of this drug combination in testicular cancer.
D001761:Bleomycin / Q000627:therapeutic use*; D002822:Choriocarcinoma / Q000188:drug therapy; D002945:Cisplatin / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D006801:Humans; D008297:Male; D013724:Teratoma / Q000188:drug therapy / Q000556:secondary; D013736:Testicular Neoplasms / Q000188:drug therapy*; D013997:Time Factors; D014747:Vinblastine / Q000627:therapeutic use*
D001761:Bleomycin; D014747:Vinblastine; D002945:Cisplatin